⚕ GalenOps field
←

SITE002-0171

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2022-09-19

AEs
7
Serious
1
Dropout signal
–

Adverse events

severe serious assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-03 (study day 65); relationship: N; serious criteria: hospitalization

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-03-08 (study day 160); relationship: N

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-20 (study day 172); relationship: not assessed

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-11-16 (study day 413); relationship: N

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-08 (study day 435); relationship: N

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-03-27 (study day 545); relationship: not assessed

severe assessed

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-05-05 (study day 584); relationship: N

Data queries

No data queries.